EGB Capital
VC Fund
EGB Capital is an investment firm.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries EGB Capital invests in
Stages EGB Capital invests in
Countries EGB Capital invests in
Investment Focus
Industry
- Biotechnology 4 (57%)
- Medical 2 (29%)
- Genetics 2 (29%)
- Software 2 (29%)
- Health Care 2 (29%)
Stage
- Seed 3 (43%)
- Pre-Seed 2 (29%)
- Series A 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Extellis
|
Extellis is a satellite imaging company focused on delivering reliable Earth observation data at an industrial scale with affordable and high-volume capacity. which allows satellites to capture real-time images in all weather conditions, 24/7. This technology enables Extellis to offer high-capacity satellite imaging that can monitor changesanywhere on Earth as they happen, overcoming limitations of current satellites that cannot take enough images daily for continuous monitoring. | $6.8M / Seed / Nov 10, 2025 | |
Izote Biosciences
|
Biomanufacturing Scale-Up Solution | $3.1M / Pre-Seed / Feb 01, 2025 | |
Sofab
|
SoFab develops and manufactures nanoparticle materials for perovskite solar cells. | $1.2M / Pre-Seed / Nov 27, 2024 | |
MiLaboratories
|
MiLaboratories' key product - MiXCR is a top-notch solution to analyze immunology sequencing data. Software is used in the vaccine, cancer, antibodies, and autoimmune diseases drug development pipelines. The original idea is based on a Nature Journal article published in 2015 and developed by founders into a cutting-edge software solutionbased on competitors' reviews by top Pharma and the academic community. | $10M / Series A / Oct 10, 2024 | |
SyntaxBio
|
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | Seed / Sep 17, 2024 | |
CellFE
|
CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells. | $22M / Series A / Sep 27, 2023 | |
C. Light Technologies
|
C. Light is a neurotech company utilizing advanced machine learning and the most accurate commercially-available eye tracker (by 150X) to assess neurological health, starting with multiple sclerosis. it is a developer of a retinal eye-tracking platform used to improve the monitoring of neurodegenerative diseases. | $4.1M / Seed / Feb 02, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does EGB Capital invest in?
EGB Capital invests primarily in Biotechnology, Medical and Genetics startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did EGB Capital last invest?
The most recent investment recorded for EGB Capital closed in Nov 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
